Deyaa Adib

Deyaa Adib

Company: Triumvira

Job title: Chief Medical Officer



As a seasoned industry leader, Dr. Adib has over 24 years of medical oncology experience in the biotechnology and pharmaceutical industries, including seven successful registrations across solid tumor and hematologic malignancy indications. He previously served as acting chief medical officer at Rain Therapeutics, where he built the oncology portfolio leading to a successful IPO, and vice president of late-stage development at Blueprint Medicines advancing the development of avapritinib approved for gastrointestinal stromal tumor and advanced systemic mastocytosis.

Dr. Adib also served as global therapeutics head for solid tumors at Baxalta, advancing the development of imalumab in colorectal cancer, non-small cell lung cancer (NSCLC) and ovarian cancer, and licensing nanoliposomal irinotecan that was subsequently approved for pancreatic cancer. In this role, he also led the efforts to secure licensing and development of a CD-19 target with Precision Biosciences in B cell malignancies and PD1, LAG3, TIM3 solid tumor targets with Symphogen, a Servier company. He also served as head of hematologic malignancies at ARIAD Pharmaceuticals (now part of Takeda) leading the global clinical program for ponatinib dose finding and line extension in chronic myeloid leukemia.

Dr. Adib has also held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma where he advanced the development of Taxotere in prostate cancer, breast cancer and gastric cancer,oxaliplatin in colorectal cancer, enzalutamide in prostate cancer, quizartinib in acute myeloid leukemia and erlotinib in NSCLC. He held multiple seats as a scientific advisory board member at several biotech companies, including Imbrium Therapeutics, a Purdue Pharma subsidiary. He also provided strategic consulting support to multiple cell therapy startups including KSQ for eTIL™ and Bellicum Pharmaceuticals for GoCAR™.

Dr. Adib obtained an M.D. from Cairo University School of Medicine in Cairo, Egypt. He completed his postgraduate training at the Anglo-American Hospital Association in Cairo, Egypt and additionally at Tufts University School of Medicine in clinical pharmacology, drug development and regulation.

Location: Greater Boston Area


For contact information, please email


A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.